1419391-16-4

Basic information

• Product Name: 2-bromo-1-(4-bromophenyl)ethanone
• Synonyms: 2-bromo-1-(4-bromophenyl)ethanone
• CAS NO: 1419391-16-4
• Molecular Weight: 508.426
• Mol File: 1419391-16-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-bromo-1-(4-bromophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-(4-bromophenyl)ethanone(1419391-16-4)
• EPA Substance Registry System: 2-bromo-1-(4-bromophenyl)ethanone(1419391-16-4)

Safety Data

• Hazardous Substances Data: 1419391-16-4(Hazardous Substances Data)

Upstream product

• 188200-05-7 1-(tertbutyloxycarbonyl)-5-(hydroxy)pyrrolidine-2-carboxylic acid methyl ester 
• 73183-34-3 bis(pinacol)diborane 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 83548-46-3 (S)-1-tert-butyl 2-methyl 2,3-dihydro-1H-pyrrole-1,2-dicarboxylate 
• 1419390-01-4 C₁₂H₁₉NO₄ 
• 1560641-93-1 C₁₉H₂₂BrNO₅ 
• 1560641-95-3 C₁₉H₂₂BrN₃O₂ 
• 1560641-97-5 C₂₅H₃₄BN₃O₄ 
• 1419391-13-1 2-bromo-1-(4-bromophenyl)ethanone 
• 1419387-48-6 C₇H₁₁NO₂ 
• 1419387-51-1 C₁₄H₂₂N₂O₅ 
• 1419387-54-4 C₁₃H₂₀N₂O₅ 

Relevant articles and documents

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.